Professor Ira Jacobson Official Opening ACADEMIC SPONSOR:



Similar documents
THE VIRAL HEPATITIS CONGRESS September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme

Briefing Note: Hepatitis B & Hepatitis C. Summary:

Hepatitis C treatment update

Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B. Issue date: February 2006

HEPATITIS COINFECTIONS

Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones

Dr. Abonyi Margit PhD SE 1st Medical Clinic Associate Professor. Hepatology-2014

Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012

DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

UPDATE ON NEW HEPATITIS C MEDICINES

Management of Chronic Hepatitis B: 2012 Update

HEPATITIS B VIRUS (HBV) & HEPATITIS C VIRUS (HCV)

HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain

Hepatitis C Class Review

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)

PURPOSE: To define the criteria to be used to determine the medical necessity of antiviral therapy in the treatment of Chronic Hepatitis B.

MarketVIEW: Hepatitis C Virus (HCV) vaccines (CAT: VAMV042) Background. ****Published February 2013***

Innovazione farmacologica e farmacologia clinica

First Announcement. 2 6 November 2014 Scottish Exhibition and Conference Centre Glasgow, UK. Joint Academic Sponsors

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas

Hepatitis C Treatment Advocacy: Ireland. Brian O Mahony

Federal Government Standing Committee on Health

Virology. Behandlung der Hepatitis B. HBV Genome. HBV life cycle. HBV Genotypes. Natural History. 8 genotypes: A, B, C, D, E, F, G, H

Newly Diagnosed: HEPATITIS C. American Liver Foundation Support Guide

HBV DNA < monitoring interferon Rx

The Hepatitis B virus (HBV)

Lancet Device Incident Investigation Report

TESTING AND MANAGEMENT. Dr Nicole Allard GP Cohealth, Joslin Clinic, West Footscray PhD student, Epidemiology Unit VIDRL

New York Hepatitis C Research Consortium September 29, 2014

Travel Medicine Travel Medicine Vaccines & Therapeutics. Brochure. International Conference on. Travel Medicine 2016

Hing wars. During World War II, there was a series of hepatitis outbreaks

Update on Hepatitis C. Sally Williams MD

National Health Burden of CLD in Italy

HBV Treatment Guidelines. By: Prof.Dr. Abdelfatah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine

Focus on Transplantation: Treatment Post-transplant for HBV and HCV

A Proposal for Managing the Harvoni Wave June 22, 2015

PROGRAMME SPECIFICATION

Liver Disease and Therapy of Hepatitis B Virus Infections

Infection with the hepatitis B virus

Optimising therapy in chronic hepatitis B: Switch or add treatment

Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B

The availability of newer antiviral agents, as

TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS

Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C

HCV RNA Monitoring System Meets Critical Need to Monitor Patient Viral Loads in Hepatitis C Virus (HCV) Clinical Trials

1.1.2 Amend the that the Special Authority relating to tenofovir for use in pregnancy for postpartum care;

Genomic Medicine Education Initiatives of the College of American Pathologists

Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?

Chronic hepatitis B (CHB) remains an important public SPECIAL REPORT

Hepatitis B. What I need to know about. National Digestive Diseases Information Clearinghouse NATIONAL INSTITUTES OF HEALTH

Institute of International Business Relations. Less theory more focus on application

D Candotti. Institut National de la Transfusion Sanguine Dept. Agents Transmissibles par le Sang Paris, France

13 September London, UK

JUNE 2-3, 2014 CONNECT.

Treatment of Hepatitis B

SIXTY-SEVENTH WORLD HEALTH ASSEMBLY. Agenda item May Hepatitis

2016 ISONG World Congress

Hepatitis B and C What Is New In Perinatal Transmission?

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL

Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total

Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?

Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS

NEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)

Treatment Strategies of Hepatitis B in China

The Immune System and Disease

MEDICAL POLICY STATEMENT

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

Hepatitis B: Objectives. Hepatitis C: Objectives. Hepatitis B: Natural History. Hepatitis B is a DNA virus and is NOT curable.

Acute HCV was defined as (3 out of 4 within the preceding 4 months):

Advanced Management Issues in HIV Medicine

ICS Summer School 2016

LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova

Hepatitis C Treatment For Injecting Drugs

Genetic testing. The difference diagnostics can make. The British In Vitro Diagnostics Association

I wish you an inspiring and successful learning experience here in Saint Petersburg. Yours Sincerely, Rachel Clark CEO, EXCEMED

Coinfezione HIV-HCV. Raffaele Bruno, MD. Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

12 TH ALL-OHIO INSTITUTE ON COMMUNITY PSYCHIATRY

Stepwise Approach for Detecting, Evaluating, and Treating Chronic Hepatitis B Virus Infection

Hepatitis C Virus Infection in Massachusetts: A tale of two epidemics

UCLA Asian Liver Program

Hepatitis B Virus Program

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT

agenda March 2015 Prague, Czech Republic

Perspective Advances in the Treatment of Hepatitis C Virus Infection

Objectives. Hepatitis C: The new era of screening and treatment. Distribution of HCV genotypes 11/1/2014. History of HCV diagnosis and screening

4 About FameLab. 7 Chair of the Jury. 7 Jury Members

ROYAL HOSPITAL FOR WOMEN

Emotion, behaviour and applied psychology in diabetes education

Ribavirin/Pegylated Interferon Combination Therapy for People with Hepatitis C

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

May 28-30, 2015 Ghent, Belgium Venue: het Pand

Enter this essay in the English Language Learner (for 5 years or less of English) category: _X_ Yes

Monitoring of Treatment of viral hepatitis C

This international event will discuss new cellular, molecular and chemical approaches to improving immunisation efficacy.

CASG HBV Study Richard B. Pollard, MD David M. Asmuth, MD Division of Infectious Diseases University of California Davis Medical Center Sacramento, CA

3.0 Treatment of Infection

Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?

Congress Theme: Global Event: Regionally Aligned: Educational Value: Committed:

Transcription:

Professor Ira Jacobson Official Opening ACADEMIC SPONSOR:

Welcome to Frankfurt and The Viral Hepatitis Congress

Development of the Congress In 2010 we recognised a high volume of compounds for HCV that might reach the market by 2016 Developments are occurring at a rapid pace Based on the success of the HIV Congress (this November will be the 11th meeting since the congress was initiated in 1990) a forum for clinicians and investigators to assimilate complex information in a rapidly developing field with an increasing array of treatment options The Scientific Committee, co-chaired by myself and Professor Stefan Zeuzem under the auspices of Weill Cornell Medical College and Goethe Universität, has collaborated on ideas and topics to develop a relevant and exciting Scientific Programme

Joint Academic Sponsors

The Viral Hepatitis Congress Scientific Committee Scientific Committee Chairs Ira Jacobson Weill Cornell Medical College, New York, USA Stefan Zeuzem J.W. Goethe University, Frankfurt, Germany Scientific Committee Nezam Afdhal Harvard Medical School, Boston, USA Antonio Craxì University of Palermo, Palermo, Italy Geoffrey Dusheiko Royal Free Hospital and University College School of Medicine, London, UK Graham Foster Queen Mary, University of London, London, UK Patrick Marcellin University of Paris, Paris, France Hendrik Reesink Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands Jürgen Rockstroh University of Bonn, Bonn, Germany

The Journey So Far

HCV Key Developments Interferon alfa Ribavirin Peginterferons Telaprevir & boceprevir Cure of HCV without IFN IL28B 1975 1986 1989 1993 1996 1997 1999 2000 2005 2008 2011 HCV identified Replicon developed Infectious virus 2a Description of non-a, non-b hepatitis Genome organization & processing determined Infectious clone developed Adaptive mutations identified Humanized mouse models established Adapted from Dr J Lemm

HBV Key Developments Adefovir Tenofovir Blood bank screening Genome sequenced Interferon alfa Lamivudine Entecavir, PEG- IFN2a Long term data on oral antivirals 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2012 Discovery of Australia antigen (HBsAg) e antigen discovered HBV particle discovered by electron microscopy Plasma vaccine Recombinant vaccine Universal immunization of infants Telbivudine

The Viral Hepatitis Congress: Our Aim Continued innovation and progress results in a wealth of new information. We aim to: Provide you with a concise update on new advances in viral hepatitis To focus on practical guidance: what the new scientific developments mean for the present and the future clinical management of viral hepatitis

Meeting Format The Scientific Programme is built around a core format of plenary sessions, so you will never miss out on the latest information This afternoon there will be two Keynote Lectures on the hepatitis B and C viruses and over the next couple of days you will have the opportunity to listen to a world renowned faculty covering a wide range of topics Interaction is encouraged; tomorrow there are panel discussions and on Sunday we have a very busy agenda but there will still be opportunities to ask questions via cards and from the floor Please visit the scientific posters that will be displayed for the duration of the congress in the Casino building

Our Programme for Today 17.30 Official Opening I. Jacobson (USA) S. Zeuzem (Germany), 18.00 Key Note Lecture: Hepatitis C Virus R. Bartenschlager (Germany) 18.30 Key Note Lecture: Hepatitis B Virus B. McMahon (USA)

We Welcome Your Participation Question cards and standing microphones are provided Please fill in the question cards during the presentation and pass to a staff member If you wish to ask a question or raise a point during the Q&A sessions, please make your way to one of the standing microphones

Thank you to our sponsors

And finally Please turn off your mobile phone This meeting has been granted 13 CME credits by the European Accreditation Council for Continuing Medical Education (EACCME). To obtain your CME credits, you must sign the register on the Congress General Information Desk on a daily basis More information on CME credits can be found in your Final Programme Booklet